STOCKHOLM, March 18, 2024 /PRNewswire/ — Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor…
Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders
This post was originally published on this site